Inovio Appoints Vice President Of Clinical Development
This article was originally published in Scrip
Inovio Pharmaceuticals, Inc. has appointed Prakash Bhuyan vice president of clinical development. He will lead the clinical development of Inovio's programs to treat HPV-related pre-cancers. Bhuyan joins the company from Pfizer where he was senior director, Pfizer vaccine research and prior to this he directed the development and execution of clinical trials for vaccines at Merck.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.